Eli Lilly agreed to pay $100 million upfront to license rights from CSL for clazakizumab, an anti‑IL‑6 monoclonal antibody, expanding Lilly’s inflammation and immunology portfolio. CSL retains certain rights, including a Phase III program in end‑stage kidney disease, while Lilly will develop the antibody in other indications with potential milestone and royalty payments to CSL. The acquisition reflects Lilly’s active external sourcing strategy to complement internal R&D, leveraging cash flows from its metabolic franchise to accelerate entry into high‑value immunology targets. IL‑6 blockade remains a validated mechanism across inflammatory diseases, and Lilly gains an additional therapeutic asset to test in broader immune‑mediated indications.